ADX71149 is a novel, first-in-class potent, oral, small molecule positive allosteric modulator (PAM) of metabotropic glutamate receptor 2 (mGlu2), a Family C class of G Protein Coupled Receptor (GPCR).
ADX71149 acts synergistically with levetiracetam (a globally commercialized antiepileptic drug) in preclinical models of epilepsy, showing efficacy both as stand alone and in combination with SV2A ligands including levetiracetam.
The development of ADX71149 is part of a worldwide research collaboration and license agreement between Addex and Janssen Pharmaceuticals, Inc. to discover, develop and commercialize a novel mGluR2 PAM medication for the treatment of anxiety, schizophrenia and other undisclosed indications. Under the terms of the agreement, Addex is eligible for up to a total of €112 million in milestone payments based on potential development and regulatory achievements. In addition, Addex is eligible for low double-digit royalties on sales of any mGluR2 PAM medication developed under the agreement.
We are working with our partner Janssen on identifying the best path to move ADX71149 into a Phase IIa proof of concept study in epilepsy.